Navigation Links
Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients

- As previously announced, primary endpoint not met; plausibly confounded by survival benefit of post-study treatment with ERBITUX -

NEW YORK, April 16, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced detailed results from the EPIC study - a randomized, open-label, multi-center Phase III trial - comparing ERBITUX(R) (Cetuximab) plus irinotecan to irinotecan alone in patients with metastatic colorectal cancer (mCRC) who failed first-line therapy. Results showed that the secondary endpoints of progression-free survival and response rate were significantly higher in the ERBITUX-irinotecan arm. The median time of survival without disease progression was improved by 54% in the patients who received ERBITUX plus irinotecan. This benefit produced a significant 31% reduction in the risk of disease progression (Hazard ratio, 0.692; 95% CI = 0.617- 0.776; p<0.0001). Additionally, patients in the ERBITUX-irinotecan arm were four times more likely to experience a 50% reduction in tumor size over patients treated with irinotecan alone (p<0.0001).

"The improvement in progression-free survival and response rate expands our understanding of the significant activity of ERBITUX," said Eric Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems. "We believe these outcomes add to the existing clinical evidence demonstrating the safety and effectiveness of ERBITUX in combination with chemotherapy."

As previously reported, the study's primary endpoint of overall survival was not different between the two groups (Hazard ratio, 0.975; 95.03% CI = 0.854 - 1.114; p=0.7115). Analysis of the data show that a considerable number of patients randomized to the irinotecan arm went on to receive ERBITUX with or without irinotecan after failing irinotecan alone. Extensive post-trial use of ERBITUX may explain the lack of difference in overall
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:8/4/2015)... New York , August 4, 2015 ... report titled " Non-invasive Prenatal Testing (NIPT) Market (BambniTest, ... and Others) - Global Industry Analysis, Size, Volume, Share, ... According to a new market report published by ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ...
(Date:8/4/2015)... BioElectronics Corporation (OTC Pink: BIEL), the ... medical devices, announced today that its registry study ... device has been published in the prominent peer ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic pain sufferers ... Chronic pain is a major ...
(Date:8/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nl392k/alcohol ) has announced the ... (Household & Personal Care, Pharmaceutical, Oilfield, Agrochemicals, and Others) ... report to their offering. The market ... in 2014 and is projected to grow at a ... data mentioned in the report is based on the ...
Breaking Medicine Technology:Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 3
... America,s Specialty Medicines Companies (ASMC), an informal working group ... concerns about H.R. 3962, the "Affordable Health Care for ... These smaller companies fear that the cumulative effect of ... their efforts to bring new medicines to market. ...
... Nov. 6 NuVasive, Inc. (Nasdaq: NUVA ), ... minimally disruptive surgical treatments for the spine, announced today ... President and Chief Financial Officer, effective November 9, 2009. ... Team updates. , "Michael will be an excellent complement ...
Cached Medicine Technology:Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962) 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5
(Date:8/4/2015)... Denver, CO (PRWEB) , ... August 04, 2015 ... ... for skilled nursing homes and other long-term care facilities, today announced details of ... (QAPI) for nursing homes and centers. , Providigm’s QAPI Accreditation program , ...
(Date:8/4/2015)... ... August 04, 2015 , ... A new report by ... reseller channel will grow at least 6 percent in 2015, as solution providers ... greater than their OEM/vendor partners. , The 2112 Group’s 2015 Midyear Channel ...
(Date:8/4/2015)... ... August 04, 2015 , ... Driving skills ... end to driving, says the August 2015 Harvard Health Letter. , "Age and ... It requires an individual assessment of skills," says Lissa Kapust, a social worker ...
(Date:8/4/2015)... ... , ... Updated enrollment data on the top U.S. health plans, as collected ... http://www.AISHealth.com . The data is free to all registered users to AISHealth.com. Based ... on the website’s “Data” section include:, , Top 25 U.S. ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... The ... designed to treat Retinitis pigmentosa, a rare eye disease that progressively causes blindness, were ... Academy of Ophthalmology. According to the results of the trial, the implant, more commonly ...
Breaking Medicine News(10 mins):Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 2Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 3Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2
... In March, AHIP,s Board of,Directors advocated for ... and Medicare Part D plan marketing activities. Today,the ... new regulations., (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ), ... beneficiaries can rely on the,information being provided to ...
... countless years of collective brainpower to rescuing princesses or ... at the University of Washington will try to harness ... even finding a cure for HIV., A new game, ... Introductory levels teach the rules, which are the same ...
... DALLAS, May 8 May has been designated Allergy ... working to educate,Americans about the conditions. Of most importance ... but especially when the environment indoors or,outdoors may trigger ... 3,800 asthma-related deaths in the,United States. The American Association ...
... Software training supplements counseling, could also treat other ... -- The use of a computer-assisted training program, ... stay abstinent longer than counseling alone, a Yale ... , The trial included 77 people who sought ...
... Calif., May 8 As injectable fillers,become mainstream ... longer lasting,and less expensive alternatives to prevent facial ... busy practice in,Beverly Hills says, "Fillers such as ... suture material. When injected into,human tissue, all of ...
... May 8 Metametrix Clinical Laboratory (, ... and metabolic testing,announced the introduction of the ... the oxidative products of,tetrahydrobiopterin (BH4)., Neopterin ... reactions,involving tetrahydrobiopterin (BH4). Restricted BH4 availability has ...
Cached Medicine News:Health News:Computer game's high score could earn the Nobel Prize in medicine 2Health News:Computer game's high score could earn the Nobel Prize in medicine 3Health News:Computer game's high score could earn the Nobel Prize in medicine 4Health News:Respiratory Therapists Offer Breath of Fresh Air During Allergy & Asthma Month 2Health News:Computer Program Helps Drug Abusers Stay Clean 2Health News:Dr. Arnold Klein Warns of Dangers With Permanent and Longer Lasting Injectable Fillers 2Health News:Metametrix Introduces the New Neopterin/Biopterin Profile 2
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours....
... T helps provide protection to the exposed airway ... extremely lightweight making it ideal for active young ... rate of heat and moisture recovery, it ensures ... HMEs and filters have ISO standard tapered ends ...
Medicine Products: